(Q44785640)

English

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

scientific article published in May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anna Dmoszyńska

12

object named as

A Dmoszynska

1 reference

Europe PubMed Central

6 December 2017

19

object named as

O Haus

1 reference

Europe PubMed Central

6 December 2017

Jerzy Hołowiecki

1

object named as

J Holowiecki

1 reference

Europe PubMed Central

6 December 2017

Sebastian Giebel

5

object named as

S Giebel

1 reference

Europe PubMed Central

6 December 2017

Sebastian Grosicki

2

object named as

S Grosicki

1 reference

Europe PubMed Central

6 December 2017

3

object named as

T Robak

1 reference

Europe PubMed Central

6 December 2017

Andrzej Hellmann

6

object named as

A Hellmann

1 reference

Europe PubMed Central

6 December 2017

Aleksander Skotnicki

7

object named as

A Skotnicki

1 reference

Europe PubMed Central

6 December 2017

9

object named as

L Konopka

1 reference

Europe PubMed Central

6 December 2017

Kazimierz Kuliczkowski

10

object named as

K Kuliczkowski

1 reference

Europe PubMed Central

6 December 2017

Krystyna Zawilska

15

object named as

K Zawilska

1 reference

Europe PubMed Central

6 December 2017

Mieczyslaw Komarnicki

16

object named as

M Komarnicki

1 reference

Europe PubMed Central

6 December 2017

Janusz Kłoczko

17

object named as

J Kloczko

1 reference

Europe PubMed Central

6 December 2017

Agnieszka Wierzbowska

24

object named as

A Wierzbowska

1 reference

Europe PubMed Central

6 December 2017

Slawomira Kyrcz-Krzemien

4

object named as

S Kyrcz-Krzemien

1 reference

Europe PubMed Central

6 December 2017

Wiktor Jedrzejczak

8

object named as

W W Jedrzejczak

1 reference

Europe PubMed Central

6 December 2017

Beata Stella-Hołowiecka

20

object named as

B Stella-Holowiecka

1 reference

Europe PubMed Central

6 December 2017

author name string

B Zdziarska

11

1 reference

Europe PubMed Central

6 December 2017

B Marianska

13

1 reference

Europe PubMed Central

6 December 2017

A Pluta

14

1 reference

Europe PubMed Central

6 December 2017

K Sulek

18

1 reference

Europe PubMed Central

6 December 2017

W Baran

21

1 reference

Europe PubMed Central

6 December 2017

B Jakubas

22

1 reference

Europe PubMed Central

6 December 2017

M Paluszewska

23

1 reference

Europe PubMed Central

6 December 2017

M Kielbinski

25

1 reference

Europe PubMed Central

6 December 2017

K Jagoda

26

1 reference

Europe PubMed Central

6 December 2017

Polish Adult Leukemia Group (PALG)

27

1 reference

Europe PubMed Central

6 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2004

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

18

1 reference

Europe PubMed Central

6 December 2017

5

1 reference

Europe PubMed Central

6 December 2017

989-997

1 reference

Europe PubMed Central

6 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403336

0 references

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Purine nucleoside analogues in the treatment of myleoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Cellular and clinical pharmacology of fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

21 January 2018

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

7 January 2021

based on heuristic

inferred from DOI database lookup

G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter stud

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

7 January 2021

based on heuristic

inferred from DOI database lookup

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403336

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403336

1 reference

Europe PubMed Central

6 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44785640&oldid=2118168448"